title: Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant.
abstract: Complexes of cationic liposomes and non-coding DNA (CLDC) have shown promise as vaccine adjuvant. Using the woodchuck animal model of hepatitis B virus (HBV) infection, the immunogenic effects of CLDC were evaluated following vaccination with three doses of woodchuck hepatitis virus surface antigen (WHsAg) adjuvanted with either CLDC or conventional alum and administered intramuscularly (im) or subcutaneously (sc). IM vaccination with WHsAg and CLDC elicited antibodies earlier, in more woodchucks, and with higher titers than WHsAg and alum. After two vaccine doses, antibody titers were higher following im than sc administration. Woodchucks administered two vaccine doses sc received the third vaccine dose im, and antibody responses reached titers comparable to those elicited by im administration. Following the second vaccine dose, im vaccination with WHsAg and CLDC induced T cell responses to WHsAg and selected WHs peptides and expression of the leukocyte surface marker CD8 and of the Th1 cytokines interferon-gamma and tumor necrosis factor alpha in woodchucks. T cell responses and CD8/cytokine expression were diminished in woodchucks from the other groups suggesting that this vaccine regimen induced a skew toward Th1 immune responses. The present study in woodchucks demonstrates that CLDC-adjuvanted WHsAg vaccine administered im resulted in a more rapid induction of humoral and cellular immune responses compared to conventional, alum-adjuvanted WHsAg vaccine. While less rapid, the immune responses following sc administration can prime the im immune responses. This adjuvant activity of CLDC over alum may be beneficial for therapeutic vaccination in chronic HBV infection.
authors.affiliation: Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, District of Columbia, USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Cote
authors.forename: Scott D
authors.initials: SD
authors.lastname: Butler
authors.forename: Andrea L
authors.initials: AL
authors.lastname: George
authors.forename: Jeffery
authors.initials: J
authors.lastname: Fairman
authors.forename: John L
authors.initials: JL
authors.lastname: Gerin
authors.forename: Bud C
authors.initials: BC
authors.lastname: Tennant
authors.forename: Stephan
authors.initials: S
authors.lastname: Menne
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000534:Alum Compounds / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000954:Antigens, Surface / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004247:DNA / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000276:immunology*; D017919:Hepatitis B Virus, Woodchuck / Q000276:immunology*; D007117:Immunization, Secondary / Q000379:methods; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000096:biosynthesis; D008081:Liposomes / Q000008:administration & dosage / Q000494:pharmacology*; D008392:Marmota; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000954:Antigens, Surface; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D008081:Liposomes; D014409:Tumor Necrosis Factor-alpha; C041524:aluminum sulfate; D007371:Interferon-gamma; D004247:DNA